These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 34953682)

  • 1. Anticancer drug resistance: An update and perspective.
    Nussinov R; Tsai CJ; Jang H
    Drug Resist Updat; 2021 Dec; 59():100796. PubMed ID: 34953682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired Resistance to KRAS
    Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ
    N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and resistance to KRAS
    Ye W; Lu X; Qiao Y; Ou WB
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Acquired Resistance to KRAS
    Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
    Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
    Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
    Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting KRAS
    Torres-Jiménez J; Espinar JB; de Cabo HB; Berjaga MZ; Esteban-Villarrubia J; Fraile JZ; Paz-Ares L
    Drugs; 2024 May; 84(5):527-548. PubMed ID: 38625662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The KRAS-G12C inhibitor: activity and resistance.
    Liu J; Kang R; Tang D
    Cancer Gene Ther; 2022 Jul; 29(7):875-878. PubMed ID: 34471232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.
    Veluswamy R; Mack PC; Houldsworth J; Elkhouly E; Hirsch FR
    J Mol Diagn; 2021 May; 23(5):507-520. PubMed ID: 33618059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model.
    Kobayashi K; Terai H; Yasuda H; Hamamoto J; Hayashi Y; Takeuchi O; Mitsuishi Y; Masuzawa K; Manabe T; Ikemura S; Kawada I; Suzuki Y; Soejima K; Fukunaga K
    Biochem Biophys Res Commun; 2021 Jan; 534():1-7. PubMed ID: 33302159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The KRAS
    Briere DM; Li S; Calinisan A; Sudhakar N; Aranda R; Hargis L; Peng DH; Deng J; Engstrom LD; Hallin J; Gatto S; Fernandez-Banet J; Pavlicek A; Wong KK; Christensen JG; Olson P
    Mol Cancer Ther; 2021 Jun; 20(6):975-985. PubMed ID: 33722854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
    Manabe T; Bivona TG
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The KRAS
    Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
    Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced
    Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP
    J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer.
    Di Federico A; Ricciotti I; Favorito V; Michelina SV; Scaparone P; Metro G; De Giglio A; Pecci F; Lamberti G; Ambrogio C; Ricciuti B
    Curr Oncol Rep; 2023 Sep; 25(9):1017-1029. PubMed ID: 37378881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
    J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Landscape of
    Salem ME; El-Refai SM; Sha W; Puccini A; Grothey A; George TJ; Hwang JJ; O'Neil B; Barrett AS; Kadakia KC; Musselwhite LW; Raghavan D; Van Cutsem E; Tabernero J; Tie J
    JCO Precis Oncol; 2022 Mar; 6():e2100245. PubMed ID: 35319967
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Ceddia S; Landi L; Cappuzzo F
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012655
    [No Abstract]   [Full Text] [Related]  

  • 19. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
    Tong X; Patel AS; Kim E; Li H; Chen Y; Li S; Liu S; Dilly J; Kapner KS; Zhang N; Xue Y; Hover L; Mukhopadhyay S; Sherman F; Myndzar K; Sahu P; Gao Y; Li F; Li F; Fang Z; Jin Y; Gao J; Shi M; Sinha S; Chen L; Chen Y; Kheoh T; Yang W; Yanai I; Moreira AL; Velcheti V; Neel BG; Hu L; Christensen JG; Olson P; Gao D; Zhang MQ; Aguirre AJ; Wong KK; Ji H
    Cancer Cell; 2024 Mar; 42(3):413-428.e7. PubMed ID: 38402609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adagrasib in Non-Small-Cell Lung Cancer Harboring a
    Jänne PA; Riely GJ; Gadgeel SM; Heist RS; Ou SI; Pacheco JM; Johnson ML; Sabari JK; Leventakos K; Yau E; Bazhenova L; Negrao MV; Pennell NA; Zhang J; Anderes K; Der-Torossian H; Kheoh T; Velastegui K; Yan X; Christensen JG; Chao RC; Spira AI
    N Engl J Med; 2022 Jul; 387(2):120-131. PubMed ID: 35658005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.